Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The large hedge funds can get direct meetings with the CEO. Even with regulation fair disclosure in place, the large hedge funds can still get one on on meetings with management. So the short answer to your question is I'm pretty sure the Baker Brothers have communicated their desires to management.
The large funds have access to management that us retail shareholders cannot get.
I hope you're right and that the company now realizes they need BP's help.
For Europe or for USA?
We are trading around $5.50 per share......$35 is wishful thinking....perhaps pre-DU.
$18 to $20 is way more realistic.
Buyout when tho? What makes you so confident BP has figured it out?
Can you explain / expound more?
How will this ultimately be bullish for Amarin?
Have you all been following what has taken place with Sava?
It's surprising our market cap is still this low relative to the other Alz plays.
What are you seeing? Which strike price?
Interesting post on stocktwits about Prepare-IT
https://stocktwits.com/Golfeux/message/372205197
Interesting. Which indication would it be for.....CVD? or High Trigs?
Can you explain how this helps us? How does this stave off generics?
I disagree.
I wonder if Pfizer is thinking about a combo pill...?
Would they need FDA approval for that...?
That certainly would be something generics cant compete with. Not getting a combo pill for high trigs.
I wonder if Pfizer is thinking about a combo pill...?
Would they need FDA approval for that...?
That certainly would be something generics cant compete with. Not getting a combo pill for high trigs.
I wonder if Pfizer is thinking about a combo pill...?
Would they need FDA approval for that...?
That certainly would be something generics cant compete with. Not getting a combo pill for high trigs.
I hope it happens before end of year. To move on.
JT was dreaming smh. Hopefully KM can get the deal done. Time is money.
LBL what are your thoughts on the Pfizer / HLS deal?
You think Pfizer could get the generics to back off.
So you think it happens before end of this year?
Very interesting. This is the agreement:
https://www.sec.gov/Archives/edgar/data/0000897448/000156459018003389/amrn-ex1068_470.htm
I have not been able to find what happens upon a change of control. I guess unless specifically spelled out typically the acquirer would assume the contract with HLS. Unless of course there is a provision that says this agreement terminates upon a change of control.
I guess you're saying that if Pfizer bought Amarin, even with the existing contract in place HLS would have more negotiating leverage with Pfizer in the event Pfizer wanted to alter the terms of their current arrangement?
Also as another poster pointed out it looks like Amarin had to give its consent for Pfizer to enter this agreement with HLS. See section 2.1.3. All very interesting. Amarin was definitely in the loop here.
2.1.3Licensee’s Right to Sublicense. Licensee shall have the right to sublicense those rights granted to it under Sections 2.1.1 and 2.1.2 to (a) Affiliates, subject to Licensee’s prior written notice to Amarin of the identity of such Affiliate and the purpose of such sublicense, and (b) Third Parties, subject to first obtaining Amarin’s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed) (each of (a) and (b), a “Sublicensee”); [***]
Thanks for sharing. I just hope this is not another Evaporate.....where we all got excited and the impact on share price was a nothing burger......
Time will tell....
They too are holding out for higher share price.
I would love to know what they communicated to Karim about BO, etc.
Great post.
The drug will not sell itself. LOL
Wow. What year was this when you mentioned they were interested in Amarin....?
Given the current state of things with covid cases rising due to delta variant the longer they wait to release Prepare-IT 2 it more than signals a lack of awareness but also starts to call into question whether they are truly interested in helping the masses or more interested in accolades....
What better time to release Prepare-IT 2 if results are good. What are they waiting for 2022.....smh
I just hope Merck saw the news.....lol
Merck missed huge with covid thus far and needs something to catch up for growth.
Article in Barron's: As Covid cases spread, vaccines won't be enough.
see below:
As Covid Cases Spread, Vaccines Won’t Be Enough
By Josh Nathan-Kazis
Aug. 16, 2021 8:45 am ET
Order Reprints
Print Article
Text size
Federal health officials have authorized third doses of Covid-19 vaccines, but the timing of the booster shots for the broader population remains unclear.
Brandon Bell/Getty Images
As cases of Covid-19 continue to climb in the U.S., some analysts are arguing that vaccines aren’t enough to fight the virus, and that a substantial commercial opportunity remains for companies that develop effective therapeutics.
The U.S. is reporting 130,800 new cases of Covid-19 per day as of Sunday, up 64% over the last 14 days. The number of deaths per day has doubled over the past two weeks, to 660.
While the rate of growth in new Covid-19 cases appears to be slowing, the daily new case count in the U.S. is now higher than it’s been at any point during the pandemic other than the period between mid-November and early February, when cases peaked.
Federal health officials on Friday authorized third doses of the Covid-19 vaccines developed by Pfizer (ticker: PFE) and Moderna (MRNA) for certain people with compromised immune systems, though were cautious not to refer to them as booster doses. Eligible people are already receiving those third doses: Local media in Oklahoma reported that one immunocompromised patient had received a third dose on Saturday at a pharmacy.
The timing of booster shots for a broader population remains unclear. “We’re looking at it on a daily and weekly basis in cohorts not only in the United States, but in other countries to determine if, when and to whom we should be giving this,” Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, said on CBS’s Face the Nation on Sunday. “So if it turns out as the data come in, we see we do need to give an additional dose to people in nursing homes, actually, or people who are elderly, we will be absolutely prepared to do that very quickly.”
more on covid
Pfizer and BioNTech Submit Covid Booster Vaccine Data to FDA
CureVac and GSK Say Second Vaccine Was Better in Preclinical Test
Surges Are ‘Entirely Preventable,’ Says Fauci
Shares of Moderna were down 0.7% in premarket trading on Monday, after a wild week last week in which the share price rose and fell sharply amid questions about the stock’s valuation. Shares of Novavax (NVAX), which is struggling to bring its own Covid-19 vaccine to market, were down 0.9%, after climbing 4.1% on Friday, while shares of Pfizer were down 0.8%, after climbing 2.6% on Friday. S&P 500 futures were down 0.3%.
On Monday, analysts at Jefferies wrote that the continued emergence of new Covid-19 variants demonstrates that vaccines won’t be enough to fight the virus. Few treatments have been developed so far, and among those, few are particularly effective. The analysts say that a substantial commercial opportunity remains for the company that develops a good Covid-19 therapeutic.
“Despite their relative lack of efficacy and lack of convenience, the small number of approved and authorized products still managed to achieve collective 1QCY21 sales of more than $3bn,” the analysts wrote. “An effective and convenient treatment could potentially achieve peak annual sales in excess of $10bn.”
The note highlights a long list of companies that are working on Covid-19 therapeutics as potential investment opportunities. “An orally available broad-spectrum antiviral, suited for immediate administration to newly diagnosed cases, would be ideal,” the analysts write. “With new Cov19 diagnoses are currently running in excess of 500,000 per day, such a drug would likely have huge commercial potential.”
The analysts write that Roche (RHHBY), the Japanese pharmaceutical company Shionogi (SGIOY), and the Hong Kong-listed Kintor Pharmaceutical (9939.HK), are all working on such orally available broad-spectrum antivirals.
The analysts say that other approaches could work, too, including neutralizing antibodies under development by AstraZeneca (AZN) and others, or immune system modulators like those being developed by Evelo Biosciences (EVLO).
What makes you think Dr. Corral did not see bad data?
It's only Prepare-IT 1 right at ESC.....I thought others including P-dude indicated it is Prepare-IT 2 that has a greater chance of success....
You must not be familiar with the missteps they have already taken. Suggest you reread Amarin's complaint. Even post the GSK / Teva first decision Hikma had already made missteps.
I'm well versed in the facts here but encourage you to reread Amarin's filing.
Then you should read Prost's dissent where she says it will be very hard for a generic to know what to do now post GSK v. Teva but again you have a different opinion. LOL
I think that ruling is helpful to us.
Porn--Judge Potter Stewart famously when trying to describe porn said "I know it, when I see it."
I disagree with you in that the generics will not gladly assume the risks here. They were banking and are banking on this not going to trial. Hoping it gets dismissed at some stage. As this gets closer to trial and with discovery....I seriously doubt the generics or Hikma for that matter wants a jury trial. The reason is that Teva can stomach a $234 mm judgement, but Hikma is a much smaller company and a judgement in the hundreds of millions for Hikma would be devastating.
The prudent thing would be for both sides to settle. We shall see.
Right now generics are at about 15K in scripts as this increases for them and their percentage share of the market.....to a jury infringement will be akin to porn....they will know it when they see it.
Discovery and damages.
btw: As Healthnet was dragged into this suit....the generics may not have the willingness of insurance companies to participate going forward. Hard to get a script for the CV indication if the CV limitation is on the label. That is blatant infringement.
Dr. Pablo Corral tweeted today:
Do you remember when clinical studies and research were published in journals so that we could all make critical reading of the information?
We looked at the tables, even the appendices.
That was also lost in a pandemic. Today are press releases, pre-prints and Tweets
Did some news leak? What is causing this SP reaction?
Any concerns about Prepare-IT not reaching statistical significance?
In terms of events....
Got it, thanks!
What makes you say that? This is not Dr. Corral's tweet.
PDude---if the results of Prepare-IT are positive how can Dr. Corral truly sit on such results knowing the devastation covid is causing? One would think this would be an ethical dilemma. Wondering if we can read anything into this that results may not be as stellar.....
I know you mentioned he believes in peer review but at the same time people are dying...
That's what happens when you have an accountant as a CEO. Not exactly skilled at marketing / promoting.
Like Reduce-IT? Wall Street nailed that one. Lol.
Wow. Moderna has a larger market cap than Merck now.
Just unreal.
It will be hard for Hikma to get around not including the CV limitation on its label. Amarin has screenshots of that and those were attached as Exhibits. That was just blatant. It is akin to having your hand in the cookie jar and being caught before your hand is removed. That is clear as day.....when Hikma launched there was no CV limitation on its label. Amarin has good facts and the case is in front of a jury.
Many people are getting caught up in the weeds here. The question to be asked is what will the general counsel of Hikma be communicating to the CEO of Hikma post GSK v. Teva about the risks of losing such a trial. It is about the risk of loss and what does that look like. Anything can happen with a jury trial but which entity in this case has more to lose. As was pointed out in the GSK trial, when there is infringement, the brand company can sue just one generic and that generic is responsible for all the lost profits form infringement from all the other generics too. Read that again: Hikma would be responsible for the lost profits emanating from all the other generics who have infringed as well.
Again the general counsel and lawyers at Hikma are having these conversations with the CEO. That's their job.
btw: Judge Newman is very smart. She knows the generics having been playing back door grab scripts via these skinny labels. So what did she do: she rewrote her opinion saying this is not a skinny label case to appease all those who weighed in about this case. Well duh in a skinny label there is no infringement but guess what there was infringement so not a true skinny label case. LOL. She is truly smart. And the beauty of it is: no en banc hearing for Teva. This is now a precedent setting case. For those who said they saw this coming......they did not. Nobody was discussing this case in the earlier parts of 2020. It arrived just in time after being heard in 2019. Thank God for Judge Newman.